Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Gains from Sales and Divestitures (2022 - 2025)

Neuroone Medical Technologies' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $36417.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 3.68% year-over-year to $36417.0; the TTM value through Dec 2025 reached $36417.0, down 3.68%, while the annual FY2025 figure was $397900.0, 47.19% up from the prior year.
  • Gains from Sales and Divestitures reached $36417.0 in Q4 2025 per NMTC's latest filing, down from $397900.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $397900.0 in Q3 2025 to a low of $32535.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 4 years is $172820.5, with a median of $136573.5 recorded in 2022.
  • The largest YoY upside for Gains from Sales and Divestitures was 903.1% in 2025 against a maximum downside of 84.62% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $40624.0 in 2022, then decreased by 7.25% to $37679.0 in 2023, then increased by 0.35% to $37809.0 in 2024, then dropped by 3.68% to $36417.0 in 2025.
  • Per Business Quant, the three most recent readings for NMTC's Gains from Sales and Divestitures are $36417.0 (Q4 2025), $397900.0 (Q3 2025), and $35771.0 (Q2 2025).